208 related articles for article (PubMed ID: 33913094)
1. MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice.
Kanno Y; Shu E; Niwa H; Seishima M; Ozaki KI
Mol Biol Rep; 2021 Apr; 48(4):3431-3437. PubMed ID: 33913094
[TBL] [Abstract][Full Text] [Related]
2. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis.
Kanno Y; Shu E; Kanoh H; Seishima M
J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600
[TBL] [Abstract][Full Text] [Related]
3. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).
Kanno Y; Kawashita E; Kokado A; Okada K; Ueshima S; Matsuo O; Matsuno H
Arthritis Rheum; 2013 Feb; 65(2):492-502. PubMed ID: 23124680
[TBL] [Abstract][Full Text] [Related]
4. α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis.
Kanno Y; Shu E; Kanoh H; Matsuda A; Seishima M
Arthritis Res Ther; 2017 Feb; 19(1):22. PubMed ID: 28159016
[TBL] [Abstract][Full Text] [Related]
5. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
6. Decrease in matrix metalloproteinase‑3 activity in systemic sclerosis fibroblasts causes α2‑antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
Niwa H; Kanno Y; Shu E; Seishima M
Mol Med Rep; 2020 Oct; 22(4):3001-3007. PubMed ID: 32945390
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
9. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
[TBL] [Abstract][Full Text] [Related]
10. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
[TBL] [Abstract][Full Text] [Related]
11. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
Bagnato GL; Irrera N; Pizzino G; Santoro D; Roberts WN; Bagnato G; Pallio G; Vaccaro M; Squadrito F; Saitta A; Altavilla D; Bitto A
Clin Sci (Lond); 2018 Jan; 132(2):231-242. PubMed ID: 29237724
[TBL] [Abstract][Full Text] [Related]
12. α2-antiplasmin positively regulates endothelial-to-mesenchymal transition and fibrosis progression in diabetic nephropathy.
Kanno Y; Hirota M; Matsuo O; Ozaki KI
Mol Biol Rep; 2022 Jan; 49(1):205-215. PubMed ID: 34709571
[TBL] [Abstract][Full Text] [Related]
13. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p.
Baral H; Uchiyama A; Yokoyama Y; Sekiguchi A; Yamazaki S; Amalia SN; Inoue Y; Ogino S; Torii R; Hosoi M; Matsuzaki T; Motegi SI
J Dermatol Sci; 2021 Oct; 104(1):39-47. PubMed ID: 34479773
[TBL] [Abstract][Full Text] [Related]
14. Bushen Yijing Decoction (BSYJ) exerts an anti-systemic sclerosis effect via regulating MicroRNA-26a /FLI1 axis.
Cheng Z; Zhang J; Deng W; Lin S; Li D; Zhu K; Qi Q
Bioengineered; 2021 Dec; 12(1):1212-1225. PubMed ID: 33843426
[TBL] [Abstract][Full Text] [Related]
15. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stem cell-derived exosomes alleviate skin fibrosis in systemic sclerosis by inhibiting the IL-33/ST2 axis via the delivery of microRNA-214.
Xie L; Long X; Mo M; Jiang J; Zhang Q; Long M; Li M
Mol Immunol; 2023 May; 157():146-157. PubMed ID: 37028129
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
Maurer B; Stanczyk J; Jüngel A; Akhmetshina A; Trenkmann M; Brock M; Kowal-Bielecka O; Gay RE; Michel BA; Distler JH; Gay S; Distler O
Arthritis Rheum; 2010 Jun; 62(6):1733-43. PubMed ID: 20201077
[TBL] [Abstract][Full Text] [Related]
18. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?
Wei J; Melichian D; Komura K; Hinchcliff M; Lam AP; Lafyatis R; Gottardi CJ; MacDougald OA; Varga J
Arthritis Rheum; 2011 Jun; 63(6):1707-17. PubMed ID: 21370225
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
[TBL] [Abstract][Full Text] [Related]
20. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
